KhoslaS.Minireview: the OPG/RANKL/RANK system. Endocrinology 2001; 142:5050–5. doi:10.1210/en.142.12.5050
2.
LaceyDLTimmsETanHL Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93:165–76. doi:10.1016/S0092-8674(00)81569-X
3.
HsuHLaceyDLDunstanCR Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 1999; 96:3540–5. doi:10.1073/pnas.96.7.3540
4.
TheillLEBoyleWJRANK-LPenninger JM. and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol 2002; 20:795–823. doi:10.1146/annurev.immunol.20.100301.064753
5.
BlairJMZhengYDunstanCR.RANK ligand. Int J Biochem Cell Biol 2007; 39:1077–81. doi:10.1016/j.biocel.2006.11.008
6.
GoriFHofbauerLCDunstanCR The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. Endocrinology 2000; 141:4768–76. doi:10.1210/en.141.12.4768
7.
KongYYYoshidaHSarosiI OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999; 397:315–23. doi:10.1038/16852
8.
DougallWCGlaccumMCharrierK RANK is essential for osteoclast and lymph node development. Genes Dev 1999; 13:2412–24. doi:10.1101/gad.13.18.2412
9.
LeibbrandtAPenningerJM.RANK/RANKL: regulators of immune responses and bone physiology. Ann N Y Acad Sci 2008; 1143:123– 50. doi:10.1196/annals.1443.016
10.
VillaAGuerriniMCassaniB Infantile malignant, autosomal recessive osteopetrosis: the rich and the poor. Calcif Tissue Int 2009; 84:1–12. doi:10.1007/s00223-008-9196-4
11.
BianchiMLBoneBardella MT. and celiac disease. Calcif Tissue Int 2002; 71:465–71. doi:10.1007/s00223-001-2131-6
12.
NobleCLMcCulloughJHoWLow body mass not vitamin D receptor polymorphisms predict osteoporosis in patients with inflammatory bowel disease. Aliment Pharmacol Ther2008; 27:588–96.
13.
Van StaaTPGeusensPBijlsmaJW Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54:3104–12. doi:10.1002/art.22117
14.
GoldringSRGravalleseEM.Mechanisms of bone loss in inflammatory arthritis: diagnosis and therapeutic implications. Arthritis Res 2000; 2:33–7. doi:10.1186/ar67
15.
KongYYFeigeUSarosiI Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999; 402:304–9. doi:10.1038/46303
16.
CohenSBDoreRKLaneNE Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arth Rheum 2008; 58:1299–309. doi:10.1002/art.23417
17.
RomasEGillespieMTMartinTJ.Involvement of receptor activator of NFkB ligand and tumor necrosis factor-a in bone destruction in rheumatoid arthritis. Bone 2002; 30:340–6. doi:10.1016/S8756-3282(01)00682-2
18.
TarantaAFortunatiDLongoM Imbalance of osteoclastogenesisregulating factors in patients with celiac disease. J Bone Miner Res 2004; 19:1112–21. doi:10.1359/JBMR.040319
19.
HofbauerLCGoriFRiggsBL Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 1999; 140:4382–9. doi:10.1210/en.140.10.4382
20.
BezerraMCCalomeniGDCaparboVF Low bone density and low serum levels of soluble RANK ligand are associated with severe arterial calcification in patients with Takayasu arteritis. Rheumatology 2005; 44:1503–6. doi:10.1093/rheumatology/kei045
21.
MoschenARKaserAEnrichB The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut 2005; 54:479–87. doi:10.1136/gut.2004.044370
22.
RogersAEastellR. Circulating osteoprotegerin and receptor activator for nuclear factor kB ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab 2005; 90:6323–31. doi:10.1210/jc.2005-0794
23.
FindlayDChehadeMTsangariH Circulating RANKL is inversely related to RANKL mRNA levels in bone in osteoarthritic males. Arthritis Res Ther 2008; 10:R2. doi:10.1186/ar2348
24.
CooperCSchafheutleKDennisonE The epidemiology of Paget’s disease in Britain: is the prevalence decreasing? J Bone Miner Res 1999; 14:192–7. doi:10.1359/jbmr.1999.14.2.192
25.
DaroszewskaARalstonSH.Genetics of Paget’s disease of bone. Clin Sci (Lond) 2005; 109:257–63. doi:10.1042/CS20050053
26.
HughesAERalstonSHMarkenJ Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat Genet 2000; 24:45–8. doi:10.1038/71667
27.
NakatsukaKNishizawaYRalstonSH.Phenotypic characterization of early onset Paget’s disease of bone caused by a 27-bp duplication in the TNFRSF11A gene. J Bone Miner Res 2003; 18:1381–5. doi:10.1359/jbmr.2003.18.8.1381
28.
WhyteMPHughesAE.Expansile skeletal hyperphosphatasia is caused by a 15-base pair tandem duplication in TNFRSF11A encoding RANK and is allelic to familial expansile osteolysis. J Bone Miner Res 2002; 17:26–9. doi:10.1359/jbmr.2002.17.1.26
29.
ChongBHegdeMFawknerM Idiopathic hyperphosphatasia and TNFRSF11B mutations: relationships between phenotype and genotype. J Bone Miner Res 2003; 18:2095–104. doi:10.1359/jbmr.2003.18.12.2095
30.
RalstonSHLangstonALPathogenesisReid IR.ofmanagement Paget’s disease of bone. Lancet 2008; 372:155–63. doi:10.1016/S0140-6736(08)61035-1
31.
RivadeneiraFStyrkársdottirUEstradaK Twenty bonemineral- density loci identified by large-scale meta-analysis of genome-wide association studies. Nat Genet 2009; 41:1199–206. doi:10.1038/ng.446
32.
BordSIrelandDC, BeaVan SR The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. Bone 2003; 32:136–41. doi:10.1016/S8756-3282(02)00953-5
33.
YanoKTsudaEWashidaN Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res 1999; 14:518–27. doi:10.1359/jbmr.1999.14.4.518
34.
RichesPLMcRorieEFraserWD Osteoporosis associated with neutralizing autoantibodies against osteoprotegerin. N Engl J Med 2009; 361:1459–65. doi:10.1056/NEJMoa0810925
35.
BekkerPJHollowayDNakanishiA The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 2001; 16:348–60. doi:10.1359/jbmr.2001.16.2.348
36.
CummingsSRMartinJSMcClungMR Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361:756–65. doi:10.1056/NEJMoa0809493
37.
HeMMSmithASOslobJD Small-molecule inhibition of TNF-a. Science 2005; 310:1022–5. doi:10.1126/science.1116304
38.
AkiyamaTShimoYYanaiH The tumor necrosis factor family receptors RANK and CD40 cooperatively establish the thymic medullary microenvironment and self-tolerance. Immunity 2008; 29:423–37. doi:10.1016/j.immuni.2008.06.015
39.
HanadaRLeibbrandtAHanadaT Central control of fever and female body temperature by RANKL/RANK. Nature 2009; 462:505–9. doi:10.1038/nature08596
